drugset / Trial / NCT00363155

KRN7000 in Chronic Hepatitis B

NCT00363155

Phase 1/2 Completed 28 enrolled Foundation for Liver Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to determine the safety, tolerability and effectiveness of KRN7000 for chronic hepatitis B infection.

Timeline

Start
2003-03
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject RGI-7000 Small molecule 0.1 ug/kg
Subject RGI-7000 Small molecule 1 ug/kg
Subject RGI-7000 Small molecule 10 ug/kg